Chemistry:CUMYL-CBMINACA
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C22H25N3O |
| Molar mass | 347.462 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
CUMYL-CBMINACA (SGT-277) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug,[1] first being identified in Germany in February 2020.[2] It is illegal in Finland.[3]
See also
- CUMYL-CBMICA
- CUMYL-CH-MEGACLONE
- CUMYL-CHMICA
- CUMYL-THPINACA
References
- ↑ "New synthetic cannabinoids carrying a cyclobutyl methyl side chain: Human Phase I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl-CBMICA and Cumyl-CBMINACA". Drug Testing and Analysis 13 (8): 1499–1515. August 2021. doi:10.1002/dta.3038. PMID 33788409.
- ↑ "EU Early Warning System Situation Report. Situation report 1". European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). June 2020. https://www.aekwien.at/documents/263869/449604/200629_EU+EARLY+WARNING+SYSTEM+SITUATION+REPORT+June.pdf.
- ↑ "Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista" (in Finnish). Finlex. Finnish Ministry of Justice. https://finlex.fi/fi/laki/ajantasa/2014/20141130#a12.11.2020-764.
 |  |
